ABL Bio, Inc.
KKRX:29838044,250.00
KRW
-250.00
(-0.56%)
ISIN
KR7298380007
Return %
Stock
S&P 500
1Y
-47.94
14.39
3Y
177.95
81.42
5Y
106.78
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sang-Hoon Lee
- Full Time Employees
- 108
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 456 Bongeunsa-ro Seoul GY South Korea 06153
- IPO Date
- Dec 21, 2018
- Website
- ablbio.com
- Similar Companies
- Business
- ABL Bio Inc. (298380.KQ) develops bispecific antibody therapeutics targeting immuno-oncology and neurodegenerative diseases; its Grabody platform enables blood-brain barrier shuttling via insulin-like growth factor 1 receptor targeting, 4-1BB agonist activation conditional on tumor antigens such as PD-L1 or ROR1 to minimize toxicity, and bispecific antibody-drug conjugates for rare blood cancers with optimized pharmacokinetics; key pipeline assets include ABL001 (tovecimig, VEGF x DLL4 for solid tumors, Phase 1/1b with U.S. FDA Fast Track), ABL111 (givastomig, Phase 1b data presented at ESMO GI 2025), ABL301 (SAR446159, transferring sponsorship to Sanofi), ABL503 (ragistomig, PD-L1 x 4-1BB, poster at ESMO IO), ABL105 (YH32367), ABL104 (YH32364), ABL202, ABL103, ABL102 (ROR1 x 4-1BB), ABL501 (PD-L1 x LAG-3), ABL602 (CLL1 bispecific T-cell engager for AML), and additional preclinical bispecific ADCs. Founded in 2016 and headquartered in Seongnam-si, South Korea, the company conducts clinical trials across the United States, China, Australia, and Korea, serving oncology and central nervous system patient populations with novel therapies to overcome PD-(L)1 resistance, enhance T-cell activation, and enable CNS drug delivery. In November 2025, ABL Bio entered a license, research, and collaboration agreement with Eli Lilly valued at up to $2.602 billion including a $40 million upfront for multiple Grabody-based therapeutics across modalities and areas like obesity and muscle diseases; it followed with a KRW 22 billion ($16 million) equity investment from Lilly via 175,079 shares at KRW 125,900 each to fund platform expansion and bispecific ADCs, pending U.S. antitrust approval; earlier, it signed a GSK licensing deal and launched U.S. spinout NEOK Bio with $75 million Series A for bispecific ADCs.